Publicacións (83) Publicacións nas que participase algún/ha investigador/a

2022

  1. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1Receptor for Parkinson's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 18, pp. 12256-12272

  2. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  3. A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  4. A Review of Population Pharmacokinetic Analyses of Linezolid

    Clinical Pharmacokinetics, Vol. 61, Núm. 6, pp. 789-817

  5. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer

    Nature Communications, Vol. 13, Núm. 1

  6. Adherencia terapéutica de ácido obeticólico: experiencia real utilizando sistemas de monitorización de medicación electrónicos

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 260-264

  7. An Experience of Using a Canvas-Based Template for Blended-Learning in a Master in Drug Discovery

    International Journal of Emerging Technologies in Learning, Vol. 17, Núm. 6, pp. 257-267

  8. Analysis of medication persistence and reasons for discontinuation of treatment with teriflunomide and dimethyl fumarate in a hospital series of patients with multiple sclerosis

    Neurology Perspectives, Vol. 2, Núm. 3, pp. 168-170

  9. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953

  10. Aumento de niveles séricos de Ciclofilina C en el seguimiento de la enfermedad arterial coronaria: un biomarcador y posible predictor clínico

    Archivos de cardiologia de Mexico, Vol. 92, Núm. 2, pp. 189-195

  11. Barriers to the Intestinal Absorption of Four Insulin-Loaded Arginine-Rich Nanoparticles in Human and Rat

    ACS Nano, Vol. 16, Núm. 9, pp. 14210-14229

  12. Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

    Dermatology and Therapy, Vol. 12, Núm. 3, pp. 761-770

  13. Capecitabine: Guaranteed access in adjuvant treatment of breast cancer

    European Journal of Hospital Pharmacy

  14. Clinical usefulness of serum angiotensin converting enzyme in silicosis

    Pulmonology

  15. Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 12

  16. Cuadro de mando de Telefarmacia: Indicadores de actividad y calidad de la atención farmacéutica de un servicio de farmacia de hospital

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 7, pp. 92-105

  17. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

  18. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab

    International Archives of Allergy and Immunology, Vol. 183, Núm. 10, pp. 1089-1094

  19. Descripción y cuantificación de las intervenciones farmacoterapéuticas al ingreso de los pacientes en un centro sociosanitario

    Pharmaceutical care España, Vol. 24, Núm. 1, pp. 20-32

  20. Design, Synthesis and 5-HT1A Binding Affinity of N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.13,7 ]decan-1-amine and N-(3-(4-(2-Methoxyphenyl) piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.13,7 ]decan-1-amine

    MolBank, Vol. 2022, Núm. 1